InNexus Biotechnology to Present at the Brean Murray, Carret & Co. Annual Institutional Investor Conference

TSX.V: IXS OTC BB: IXSBF 


VANCOUVER, Jan. 31  /PRNewswire-FirstCall/ -- InNexus today announced that Dr. Charles Morgan, President & CEO will be presenting at Brean Murray, Carret & Co. annual Institutional Investor Conference on February 1st, 2006 at 8:30. The conference will be held at The Grand Hyatt New York Hotel.

A link to the live web cast and recording of InNexus' presentation will be available on the Company's website http://www.innexusbiotech.com/. The recording of InNexus' presentation will be available beginning February 2nd, 2006, until approximately March 1, 2006.

About InNexus

InNexus is developing the next generation of therapeutic, monoclonal antibodies using its SuperAntibody Technology Platform. InNexus intends to apply this technology to improve the potency of existing antibody products while opening new markets and disease applications with other forms of SuperAntibodies. InNexus will develop the technology through partnerships with biotechnology and pharmaceutical companies while pursuing development of its own products for unmet medical needs. To learn more about InNexus please visit the Company's website: http://www.innexusbiotech.com/

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts and are subject to risks and uncertainties which could cause actual results and the timing of certain events to differ materially from those set forth in or implied herein including, without limitation, risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims litigation and other risks associated with the Company's proposed activities.

  On behalf of the Board of Directors of InNexus Biotechnology Inc.

  "signed"

  Dr. A. Charles Morgan
  President


  Contacts

  Investor Relations:
  Toll-free: 1-866-990-8382

  


  The TSX Venture Exchange has neither approved nor disapproved of the
  information contained herein.


DATASOURCE: InNexus Biotechnology, Inc.



CONTACT: Investor Relations: Toll-free: 1-866-990-8382,

Copyright